Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer

Alessandro Del Conte, Emilio Minatel, Domenico Schinella, Tanja Baresic, Stefano M M Basso, Franco Lumachi

Research output: Contribution to journalArticle

Abstract

Gefitinib is highly active in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene. The feasibility and the degree of response to treatment with gefitinib in patients with chronic renal failure (CRF) undergoing hemodialysis has not yet been fully described in literature. We describe the case of a 70-year-old man with CRF undergoing hemodialysis three times-a-week who developed vertebral and rib bone metastasis three years after lobectomy. The bone biopsy confirmed the pulmonary origin and pyrosequencing analysis revealed deletion in E746-E750 of exon 19. We started daily administration of 250 mg gefitinib with no changes in the hemodialysis schedule. Gefitinib was well-tolerated without any adverse event. After three months, the 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) showed complete metabolic remission of bone lesions. The patient is still under treatment and maintains response (30 months to date). To our knowledge, this is the first description of complete metabolic remission in this type of patient. In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases.

Original languageEnglish
Pages (from-to)319-322
Number of pages4
JournalAnticancer Research
Volume34
Issue number1
Publication statusPublished - Jan 1 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Renal Dialysis
Neoplasm Metastasis
Bone and Bones
Chronic Kidney Failure
erbB-1 Genes
Mutation
Ribs
Epidermal Growth Factor Receptor
Exons
Appointments and Schedules
gefitinib
Biopsy
Glucose
Lung
Therapeutics

Keywords

  • Bone metastasis
  • Gefitinig
  • Hemodialysis
  • Lung cancer
  • NSCLC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Del Conte, A., Minatel, E., Schinella, D., Baresic, T., Basso, S. M. M., & Lumachi, F. (2014). Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Research, 34(1), 319-322.

Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. / Del Conte, Alessandro; Minatel, Emilio; Schinella, Domenico; Baresic, Tanja; Basso, Stefano M M; Lumachi, Franco.

In: Anticancer Research, Vol. 34, No. 1, 01.01.2014, p. 319-322.

Research output: Contribution to journalArticle

Del Conte, A, Minatel, E, Schinella, D, Baresic, T, Basso, SMM & Lumachi, F 2014, 'Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer', Anticancer Research, vol. 34, no. 1, pp. 319-322.
Del Conte A, Minatel E, Schinella D, Baresic T, Basso SMM, Lumachi F. Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Research. 2014 Jan 1;34(1):319-322.
Del Conte, Alessandro ; Minatel, Emilio ; Schinella, Domenico ; Baresic, Tanja ; Basso, Stefano M M ; Lumachi, Franco. / Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. In: Anticancer Research. 2014 ; Vol. 34, No. 1. pp. 319-322.
@article{0000f8e327b44d29876daf81942658a8,
title = "Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer",
abstract = "Gefitinib is highly active in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene. The feasibility and the degree of response to treatment with gefitinib in patients with chronic renal failure (CRF) undergoing hemodialysis has not yet been fully described in literature. We describe the case of a 70-year-old man with CRF undergoing hemodialysis three times-a-week who developed vertebral and rib bone metastasis three years after lobectomy. The bone biopsy confirmed the pulmonary origin and pyrosequencing analysis revealed deletion in E746-E750 of exon 19. We started daily administration of 250 mg gefitinib with no changes in the hemodialysis schedule. Gefitinib was well-tolerated without any adverse event. After three months, the 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) showed complete metabolic remission of bone lesions. The patient is still under treatment and maintains response (30 months to date). To our knowledge, this is the first description of complete metabolic remission in this type of patient. In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases.",
keywords = "Bone metastasis, Gefitinig, Hemodialysis, Lung cancer, NSCLC",
author = "{Del Conte}, Alessandro and Emilio Minatel and Domenico Schinella and Tanja Baresic and Basso, {Stefano M M} and Franco Lumachi",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "319--322",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer

AU - Del Conte, Alessandro

AU - Minatel, Emilio

AU - Schinella, Domenico

AU - Baresic, Tanja

AU - Basso, Stefano M M

AU - Lumachi, Franco

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Gefitinib is highly active in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene. The feasibility and the degree of response to treatment with gefitinib in patients with chronic renal failure (CRF) undergoing hemodialysis has not yet been fully described in literature. We describe the case of a 70-year-old man with CRF undergoing hemodialysis three times-a-week who developed vertebral and rib bone metastasis three years after lobectomy. The bone biopsy confirmed the pulmonary origin and pyrosequencing analysis revealed deletion in E746-E750 of exon 19. We started daily administration of 250 mg gefitinib with no changes in the hemodialysis schedule. Gefitinib was well-tolerated without any adverse event. After three months, the 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) showed complete metabolic remission of bone lesions. The patient is still under treatment and maintains response (30 months to date). To our knowledge, this is the first description of complete metabolic remission in this type of patient. In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases.

AB - Gefitinib is highly active in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene. The feasibility and the degree of response to treatment with gefitinib in patients with chronic renal failure (CRF) undergoing hemodialysis has not yet been fully described in literature. We describe the case of a 70-year-old man with CRF undergoing hemodialysis three times-a-week who developed vertebral and rib bone metastasis three years after lobectomy. The bone biopsy confirmed the pulmonary origin and pyrosequencing analysis revealed deletion in E746-E750 of exon 19. We started daily administration of 250 mg gefitinib with no changes in the hemodialysis schedule. Gefitinib was well-tolerated without any adverse event. After three months, the 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) showed complete metabolic remission of bone lesions. The patient is still under treatment and maintains response (30 months to date). To our knowledge, this is the first description of complete metabolic remission in this type of patient. In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases.

KW - Bone metastasis

KW - Gefitinig

KW - Hemodialysis

KW - Lung cancer

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84897025626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897025626&partnerID=8YFLogxK

M3 - Article

C2 - 24403481

AN - SCOPUS:84897025626

VL - 34

SP - 319

EP - 322

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -